David D. Halbert - 06 Mar 2026 Form 4 Insider Report for Caris Life Sciences, Inc. (CAI)

Reporting relationship: Founder, Chairman, and Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: CAI
Reported as of: 06 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Mar 2026, 17:55:42 UTC
Prior SEC filing: 13 Aug 2025
Next SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

David D. Halbert filed Form 4 for Caris Life Sciences, Inc. (CAI) on 10 Mar 2026.

Key facts

This page summarizes David D. Halbert's Form 4 filing for Caris Life Sciences, Inc. (CAI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Mar 2026, 17:55.

Change

Previous filing in this sequence was filed on 13 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001034380 Primary reporting owner

HALBERT DAVID D

Relationship: Founder, Chairman, and Chief Executive Officer, Director, 10%+ Owner
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 10 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Award

Transaction value
Shares: +320,112
Change %: +14%
Price: $0.000000^*
Shares after: 2,615,245
Date: 06 Mar 2026
Ownership: Direct
Footnotes: F1

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 121,025,002
Date: 06 Mar 2026
Ownership: See Footnotes
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Footnote F2

The Common Stock reported herein includes (i) 76,261,532 shares of Common Stock held of record by Caris Halbert, L.P., (ii) 8,528,805 shares of Common Stock held of record by ADAPT I Ltd., (iii) 8,414,427 shares of Common Stock held of record by Carisome I, L.P., (iv) 645,149 shares of Common Stock held of record by Caris Investment II Ltd, (v) 2,175,089 shares of Common Stock held of record by Caris Investment III Ltd, and (vi) 25,000,000 shares held of record by Halbert Family Capital, LLC. Caris Investment Management, LLC is the general partner of each of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. Caris Halbert, L.P. is the managing member of Halbert Family Capital, LLC.

Footnote F3

David Dean Halbert is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.

SEC remarks

Founder, Chairman, and Chief Executive Officer